Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab with lenalidomide followed by tafasitamab monotherapy within its marketing authorisation for treating adults with relapsed or refractory diffuse large B-cell lymphoma.
Status In progress
Process STA 2018
ID number 3795

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
26 August 2020 - 24 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance